Testing Effective Methods to Recruit Sexual and Gender Minority Cancer Patients for Cancer Studies

翻译后摘要：最近，NCI呼吁研究，以有效地研究小或罕见的人群相关的癌症 research.性和性别少数群体（SGM）是患癌症风险不成比例的少数群体， 在癌症研究中研究不足。本行政补充申请，以回应MD-22- 032，寻求资金，以解决一个重要的，不可预见的挑战，在研究性和性别少数 癌症患者。SGM面临的主要共同挑战是制定有效的方法来识别和 招募这些患者和幸存者参加NCI癌症研究。在我们母研究的目标1中，我们将记录， 深度，SGM对参与NIH癌症研究的态度，确定促进者和障碍， 影响参与意愿。我们还将调查任何影响歧视和穷人的癌症护理 在研究参与方面。我们将招募顺性别SM男性，顺性别SM女性和性别少数 癌症患者（每组n=15），并比较这些小人群和SGM之间的经验 以及一个顺性别和异性恋患者对照组。 这种方法将促进我们理解为什么SGM可能缺失或系统性排除 从癌症研究。最近，研究人员强调了将性别少数群体瓦解为 单一类别。性别非二元是一个快速增长的身份标签，代表那些认同 性别不同于（或不完全是）女性或男性，并且个人可能认为或不认为自己是 跨性别者（TG）。因此，非二元患者在癌症治疗中可能面临与TG不同的挑战 患者和值得单独研究。同样，TG男性和TG女性可能有不同的 治疗的经验。将这些性别群体聚集在一起可能会掩盖重要的子群体 差异因此，我们希望扩大我们目前的研究。而不是将性别少数群体瓦解为 一个单一的组，我们将招募和采访多达15个TG男性，15个TG女性，和15个nonbinary患者（N=45 他们的癌症治疗经验和他们对参加NIH癌症的态度 research.这一形成性研究阶段的结果将为我们如何处理少数性别数据提供信息。 目标3中的定量研究。影响包括首次对性别非二元癌症患者进行的研究。

Abstract: Recently, NCI called for research to effectively study small or rare populations relevant to cancer research. Sexual and gender minorities (SGM) are small populations at disproportionate risk for cancer and are under-researched in cancer studies. This administrative supplement application, in response to MD-22- 032, seeks funding to address an important, unforeseen challenge in research on sexual and gender minority cancer patients. The principal challenge common across SGM is to develop effective methods to identify and recruit such patients and survivors into NCI cancer studies. In Aim 1 of our parent study, we will document, in depth, SGM’s attitudes towards participating in NIH cancer research, identifying facilitators and barriers that influence willingness to participate. We will also investigate any impact discrimination and poor cancer care has on research participation. We will recruit cisgender SM men, cisgender SM women and gender minority cancer patients (n=15 per group) and compare experiences within these small populations and between SGM and a cisgender, heterosexual patient comparison group. This approach will advance our understanding of why SGM may be missing or systematically excluded from cancer studies. Recently, researchers have highlighted the limitations of collapsing gender minorities into a single category. Gender nonbinary is a fast-growing identity label that represents persons who identify with a gender different than (or not exclusively as) woman or man and who may or may not personally identify as transgender (TG). As such, nonbinary patients may have different challenges in cancer treatment than TG patients and deserve to be studied separately. Similarly, TG men and TG women are likely to have different experiences of treatment. Aggregating these gender groups into one may mask important subgroup differences. For this reason, we seek to expand our current study. Instead of collapsing gender minorities into a single group, we will recruit and interview up to 15 TG men, 15 TG women, and 15 nonbinary patients (N=45 total) on both their experience of cancer treatment and on their attitudes towards participating in NIH cancer research. Results from this formative research phase will inform how to treat gender minority data for our quantitative study in Aim 3. Impact includes the first study of gender nonbinary cancer patients ever conducted.